Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
8.95
+0.01 (0.11%)
At close: Nov 22, 2024, 4:00 PM
9.18
+0.23 (2.57%)
After-hours: Nov 22, 2024, 4:05 PM EST
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 28 employees as of December 31, 2023. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change (1Y)
-1
Growth (1Y)
-3.45%
Revenue / Employee
n/a
Profits / Employee
-$2,029,750
Market Cap
559.83M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
GRAIL | 1,360 |
CureVac | 1,172 |
Talkspace | 472 |
Axogen | 428 |
Surmodics | 376 |
Humacyte | 185 |
Annexon | 71 |
Savara | 37 |
CRVS News
- 9 days ago - Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis - GlobeNewsWire
- 10 days ago - Corvus Pharmaceuticals: The Market Likes The Story - Seeking Alpha
- 10 days ago - Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 14 days ago - Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer - GlobeNewsWire
- 18 days ago - Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 - GlobeNewsWire
- 2 months ago - Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm - Business Wire
- 2 months ago - Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma - GlobeNewsWire